Fenofibrate

Overview

Fenofibrate is a selective PPARα agonist with an EC 50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC 50 s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19 , CYP2B6 , CYP2C9 , CYP2C8 , and CYP3A4 , respectively.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Viral Infection | Products > Disease Areas > Depression | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Cancer | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PPAR | Products > Signaling Pathways > Cytochrome P450 | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-17356
• CAS No.: 49562-28-9
• Molecular Formula: C20H21ClO4
• Molecular Weight: 360.83
• Purity: 99.97%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 2.5 mg/mL (6.93 mM); Clear solution
• Availability: In-stock

Source

Original product source